[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Yohanes Firmansyah, dr, MH, MM\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":71},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":13,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100632096",false,"NCT07509242","Comparative Efficacy of hUCMSC-Secretome Delivered Via Microneedling and Intradermal Microinjection as Adjuvant Therapy to NB-UVB in Nonsegmental Vitiligo: A Quasi-Experimental Study","Vitiligo","Inclusion Criteria:\n\n* Patients with a diagnosis of non-segmental vitiligo (established by a dermatologist).\n* Age 18-60 years.\n* Fitzpatrick skin types III-V.\n* Stable vitiligo lesions for at least 6 months (no new lesions and no lesion expansion \\>10% of body surface area within the past 6 months).\n* Total lesion involvement of 1-20% body surface area (BSA).\n* Willing to comply with the full course of therapy and all scheduled follow-up visits during the study.\n* Provision of written informed consent.\n\nExclusion Criteria:\n\n* Segmental, universal, or other vitiligo types that are difficult to standardize (e.g., lesions limited to the genital area).\n* Currently receiving or having received within the past 3 months:\n* Systemic immunomodulatory or immunosuppressive therapy (e.g., systemic corticosteroids, cyclosporine, methotrexate, JAK inhibitors, etc.).\n\nOther phototherapy modalities (e.g., PUVA, excimer laser) within the past 3 months.\n\n* History of keloid formation or hypertrophic scarring at the treatment sites.\n* Active infection at the lesion sites (bacterial, viral, or fungal) or other skin diseases that may interfere with pigmentation assessment.\n* Pregnancy or breastfeeding.\n* History of skin cancer, lupus, or other photosensitive disorders.\n* Severe allergy to secretome components or gel excipients (if known).\n* Uncontrolled systemic diseases (e.g., heart failure, renal failure, active systemic autoimmune disease) that may compromise follow-up compliance.","ALL","18 Years","60 Years",{"count":19,"type":20},150,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE2","PHASE3","The goal of this clinical trial is to analyze the effectiveness of SM-hUCMSC secretome administered via microneedling and intradermal microinjection as adjuvant therapy to NB-UVB, compared with NB-UVB alone, in terms of repigmentation, onset of improvement, safety, patient satisfaction, and vitiligo recurrence. The main questions it aims to answer are:\n\n* Are there differences in the level of vitiligo lesion repigmentation among the secretome therapy via microneedling, intradermal microinjection, and NB-UVB phototherapy groups?\n* Are there differences in the time to onset of repigmentation among the treatment groups? What are the safety profiles and adverse events associated with each treatment modality?\n* Are there differences in patient satisfaction and quality of life after undergoing each therapy?\n* Are there differences in vitiligo recurrence rates during the follow-up period among the treatment groups?\n\nParticipants will be allocated into three groups as follows:\n\n* Group A receives NB-UVB combined with microneedling and topical 10% secretome.\n* Group B receives NB-UVB combined with intradermal secretome injection.\n* Group C receives NB-UVB alone. The intervention period lasts 12 weeks, with follow-up until week 24.",[13],[28,29,30,31,13],"Dermatology","Microneedling","NB-UVB","Secretome","NOT_YET_RECRUITING","2026-03-28",{"date":35,"type":36},"2026-04-03","ACTUAL",{"date":38,"type":20},"2026-03-18",{"date":40,"type":20},"2028-01-18",{"name":42,"class":43},"Yohanes Firmansyah, dr, MH, MM","OTHER",1,{"id":46,"slug":4,"hasResults":10,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":10,"sex":15,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":56,"briefSummary":58,"conditions":59,"keywords":60,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":70,"locationsCount":44},"100631756","NCT07504822","Comparative Effectiveness of Clindamycin-Retinoid, Clindamycin-Retinoid-Dexamethasone, and 10% SM-hUCMSC Secretome Gel in the Improvement of Mild-to-Moderate Acne Vulgaris","Comparative Effectiveness of Clindamycin-Retinoid, Clindamycin-Retinoid-Dexamethasone, and 10% SM-hUCMSC Secretome Gel in the Improvement of Mild-to-Moderate Acne Vulgaris: A Quasi-Experimental Study","Acne Vulgaris","Inclusion Criteria:\n\n* Age 15-40 years.\n* Clinical diagnosis of mild to moderate acne vulgaris on the facial area.\n* Primary lesion location on the face, with a total lesion count meeting the above criteria.\n* Not currently using topical or systemic acne therapy within: the past 2 weeks for topical therapy; the past 4 weeks for systemic therapy (oral antibiotics, isotretinoin, or systemic steroids).\n* Willing to use only the treatment regimen provided by the investigators on the facial area throughout the study period.\n* Willing to adhere to the scheduled follow-up visits (weeks 0, 2, 4, and 8) and to sign informed consent.\n\nExclusion Criteria:\n\n* Presence of other facial skin diseases that may interfere with acne assessment (e.g., rosacea, contact dermatitis, impetigo, fungal infections, herpes, etc.).\n* History of hypersensitivity or allergy to clindamycin, retinoids, topical corticosteroids, or any components of the secretome gel.\n* Use of oral isotretinoin within the past 6 months.\n* Pregnancy or breastfeeding.\n* History of severe immunological disorders or uncontrolled systemic diseases (e.g., uncontrolled diabetes mellitus, severe liver or kidney disease).\n* Presence of extensive open wounds or active infections on the face.\n* Undergoing aggressive facial cosmetic procedures within the past 3 months (e.g., ablative laser, deep chemical peeling, dermabrasion).","15 Years","40 Years",{"count":55,"type":20},189,[57,23],"PHASE1","The goal of this clinical trial is to etermine and compare the effectiveness of three therapeutic regimens for mild to moderate acne vulgaris, such as, clindamycin-retinoid combination, clindamycin-retinoid-dexamethasone combination, and sekretome SM-hUCMSC 10% gel. The main questions it aims to answer are :\n\n* Is there a change in the number of inflammatory lesions (papules, pustules, nodules) and non-inflammatory lesions (open and closed comedones) before and after treatment in each treatment group?\n* Is there a difference in the reduction of acne vulgaris severity scores among the three treatment groups?\n* Are there differences in the rate of clinical improvement (time required to achieve a certain reduction in lesion count or severity score) among the treatment groups?\n* What are the incidence and characteristics of local adverse effects (erythema, burning sensation, skin dryness, irritation, hypo-\u002Fhyperpigmentation, and others) in each treatment group?\n* Are there differences in the impact of each therapeutic regimen on the risk of acne scar formation and improvement in skin quality (texture, elasticity, and color homogeneity)?\n* Does secretome gel demonstrate sufficient clinical potential and urgency as a safer and more prospective topical therapeutic alternative for acne vulgaris compared with retinol-clindamycin and retinol-clindamycin-dexamethasone 0.1% combinations?\n\nParticipants will be allocated into three groups using simple block randomization.\n\n* Group A will receive a combination of clindamycin and a retinoid, applied thinly to the entire facial area once daily at night.\n* Group B will receive a combination of clindamycin, a retinoid, and dexamethasone, with the same method of application as Group A.\n* Group C will receive 10% SM-hUCMSC secretome gel, applied thinly to acne-affected areas twice daily (morning and night).",[50],[61,62,63,64,31],"Acne vulgaris","Clindamycin","Dexamethasone","Retinoid",{"date":66,"type":36},"2026-04-01",{"date":68,"type":20},"2026-04-18",{"date":40,"type":20},{"name":42,"class":43},""]